VRTX starts VX 135+ Ribavirin phase II combination trial
12 week oral drug in 2 different doses and follow up SVR 4, 12 and 24 i.e total 36 week ( 6 months duration). Study is expected to finish in 12/2013. VRTX is definately putting a good effort.
ABT is pouring money into trials and I think ABT will defeat GILD in all oral race, both in timings and efficacy.
Soon to follow is announcement of initiation of combination trials with VX 135 with GSK's and JNJ's drugs, and VX 135 with Vertex's other hep C assets (telaprevir and VX 222), and more importantly the initiation in early 2013 of Phase 3 809/770 trials, and initiation of clinical trials of VX 509 in other inflammatory diseases. Of course VX 661/770 trial results should be a major catalyst as well in the first half of 2013. The potential for VX 787 will hopefully be revealed around the next two investor conferences in the coming weeks.